Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

The primary endpoint of MOUSEION-01 was to assess overall survival (OS) in male and
female patients receiving immune checkpoint inhibitors versus control treatments …

BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …

Human T cells coordinate adaptive immunity in diverse anatomic compartments through
production of cytokines and effector molecules, but it is unclear how tissue site influences T …

Melanoma, a skin cancer associated with high mortality rates, is highly radio-and
chemotherapy resistant but can also be very immunogenic. These circumstances have led to …

Immune checkpoint inhibitors have emerged as a pillar in the management of advanced
malignancies. However, nonspecific immune activation may lead to immune-related adverse …

Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …

CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are
responsible for various aspects of T-cell immune regulation. The family includes CD28 …

FOXP3-expressing regulatory T (Treg) cells, which suppress aberrant immune response
against self-antigens, also suppress anti-tumor immune response. Infiltration of a large …

Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐
stages of OC are linked with high morbidity and low survival rates despite the immense …